Immunovant, Inc. (IMVT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Eric Venker.
IMVT tiene fecha de IPO 2019-06-21, 362 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $5.4B.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies to treat autoimmune diseases. The company's lead candidate, batoclimab, is a fully human monoclonal antibody that selectively inhibits the neonatal fragment crystallizable receptor and is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials recently initiated for warm autoimmune hemolytic anemia. Founded in 2018 and headquartered in New York, Immunovant operates as a subsidiary of Roivant Sciences Ltd.
